Consensus Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
22.8 ^USD	+2.66%		-0.65%	-29.80%

Apr. 22	Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	CI
Apr. 15	Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	CI

Evolution of the average Target Price on Corcept Therapeutics Incorporated

Price target over the last 5 years

History of analyst recommendation changes

284964916a453ec95c0ab.NOufth3XoI88QIgmu9R08olAiH4NgDpzDElqhN-RMaA.eJvG51aBw-AMd8Jx-KcNpdt0-idZ6EsnbSYu3LrzCcx2iv2Abrn6_28UzQ~9f3f636b0b9e4c2d79e19912f024414f

Analyst Recommendations on Corcept Therapeutics Incorporated

Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating	Feb. 16	MT
HC Wainwright Adjusts Corcept Therapeutics' Price Target to $28 From $34, Keeps Buy Rating	Jan. 02	MT
Canaccord Genuity Adjusts Corcept Therapeutics' Price Target to $38 From $37, Keeps Buy Rating	Dec. 13	MT
Truist Upgrades Corcept Therapeutics to Buy Rating From Hold, Adjusts Price Target to $38 From $29	Nov. 06	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $34 From $32, Keeps Buy Rating	Nov. 02	MT
Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $35 From $34, Maintains Buy Rating	23-08-25	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $29 From $26, Maintains Hold Rating	23-08-03	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $32 From $30, Maintains Buy Rating	23-08-03	MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $26 From $28, Maintains Hold Rating	23-05-26	MT
SVB Securities Initiates Corcept Therapeutics at Market Perform With $25 Price Target	23-04-11	MT
Piper Sandler Starts Corcept Therapeutics at Overweight With $27 Price Target	23-04-04	MT
Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $32 From $33, Maintains Buy Rating	23-03-08	MT
Jefferies Downgrades Corcept Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $35	23-02-15	MT
HC Wainwright Cuts Price Target on Corcept Therapeutics to $30 From $33, Reiterates Buy Rating	22-12-09	MT
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $33 From $29, Reiterates Buy Rating	22-08-04	MT
Truist Securities Downgrades Corcept Therapeutics to Hold From Buy; Price Target is $30	22-08-01	MT
Canaccord Genuity Starts Corcept Therapeutics at Buy with $30 Price Target	22-02-02	MT
Truist Securities Starts Corcept Therapeutics at Buy With $30 Price Target	22-01-28	MT
CORCEPT THERAPEUTICS INCORPORATED : HC Wainwright Adjusts Corcept Therapeutics' Price Target to $29 From $32, Keeps Buy Rating	21-06-23	MT
CORCEPT THERAPEUTICS INCORPORATED : HC Wainwright Adjusts Corcept Therapeutics' Price Target to $32 From $22, Keeps at Buy	20-11-27	MT
CORCEPT THERAPEUTICS INCORPORATED : HC Wainwright Adjusts Corcept Therapeutics' Price Target to $22 From $18, Keeps Buy Rating	20-11-04	MT